Drugs - HealthQuill

British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic disorder.

AstraZeneca in $1.92 million deal with HK-listed CSPC Pharmaceutical

British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic.

by HealthQuill
October 7, 2024
0 Comments

he Democratic Republic of the Congo has started mpox vaccination aiding efforts to halt the spread of the viral disease, according to the World Health Organization.

Drugs Health Medical

Congo begins mpox vaccination in eastern region, roll-outs in 11 provinces

he Democratic Republic of the Congo has started mpox vaccination aiding efforts to halt the spread of the viral disease, according to the.

by HealthQuill
October 6, 2024
0 Comments

Global corporations worldwide are now adapting to a "new normal," where WFH is becoming standard practice, either fully or partially. While seeking a "new normal," there is growing concern about mental health outcomes associated with WFH. A study examining WFH experiences during lockdown found that most respondents reported more positive than negative experiences.

Drugs Health Medical Opinion

Opinion: Work from home debate rages on as Mental Health Day nears

By Aparna S As we inch toward October 10, Mental Health Day, the ‘Workplace Mental Health’ theme for 2024 needs to be put.

by HealthQuill
October 6, 2024
0 Comments

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

Drugs Health Pharma

Johnson & Johnson stops mid-stage trial of drug for dengue prevention

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

by HealthQuill
October 5, 2024
0 Comments

Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's immune system to attack red blood cells, for an upfront $825 million.

Drugs Health Pharma

Recordati buys Sanofi’s drug for autoimmune disease for $825 million

Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.

by HealthQuill
October 5, 2024
0 Comments

Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments globally.

Climate Drugs Pharma

Denmark’s Novo Nordisk to invest $158 million in Brazil insulin facility

Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments.

by HealthQuill
October 5, 2024
0 Comments

The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.

Drugs Health Pharma

EMA starts review of medicines to treat hair loss, prostate enlargement

The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.